JAMA Clinical Reviews Ovarian Cancer Prevention With Opportunistic Fallopian Tube Removal
9 snips
Feb 2, 2026 Jurgen M. Piek, gynecologic oncologist and researcher focused on ovarian cancer prevention, discusses opportunistic removal of fallopian tubes during pelvic surgeries. He covers the shift recognizing tubes as a cancer origin, evidence for large risk reduction, minimal impact on ovarian function, practical surgical timing, and strategies to expand safe implementation.
AI Snips
Chapters
Transcript
Episode notes
Fallopian Tube As Cancer Origin
- High-grade serous ovarian cancers often originate in the fallopian tube rather than the ovary.
- Jurgen M. Piek discovered dysplastic changes in tubes not ovaries in high-risk women, shifting the paradigm of origin.
Significant Risk Reduction With Salpingectomy
- Large cohort studies associate bilateral salpingectomy with substantially lower tubo-ovarian carcinoma risk.
- Systematic review data suggest up to an 80% risk reduction and potential 15% lower ovarian cancer mortality if widely adopted.
Short-Term Ovarian Reserve Intact
- Short-term studies show no significant change in ovarian reserve markers after salpingectomy.
- Evidence uses AMH, AFC, FSH, and estradiol, but long-term effects remain unknown.